Liver Fibrosis Treatment Market| Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• LIVER FIBROSIS TREATMENT MARKET ANALYSIS
• Liver Fibrosis Treatment Market, by Treatment
  Type (Peroxisome Proliferator-activated Receptors
  (PPAR)-alpha agonist, ACE Inhibitors,
  Hepatotropic Drug, and Others), by Condition
  (Chronic Liver Diseases, Hepatitis C, and
  Nonalcoholic Steatohepatitis), by End User
  (Hospitals, Specialty Clinics, and Others), and
  by Region (North America, Latin America, Europe,
  Asia Pacific, the Middle East, and Africa) -
  Size, Share, Outlook, and Opportunity Analysis,
  2018 2026
• The global liver fibrosis treatment market size
  is expected to witness a CAGR of 10.8 over the
  forecast period (2018 2026) reaching a value of
  US 28.1 billion in 2026.

3

• Liver fibrosis is characterized by repeated or
  continuous damage to liver resulting in an
  abnormally large amount of scar tissue in the
  liver. Fibrosis does not show any symptoms,
  however severe scarring results into cirrhosis,
  which further leads to cause symptoms. To detect
  the severity of disease, healthcare professionals
  conduct blood and imaging test, followed by liver
  biopsy, if required. In the possible treatment
  options for liver fibrosis, healthcare
  professionals focus on treating the cause, which
  often stops and slowdowns further scarring of
  liver and results in improvement of condition.
  The possible treatment options for liver fibrosis
  include use of antiviral drugs, removal or
  dissolve of a blockage in the bile ducts,
  lifestyle changes such as lower consumption of
  alcohol, control regime for obesity and
  overweight, and controlling blood sugar lipid
  levels in people with nonalcoholic fatty liver.
  
• Furthermore, research funding by various private
  research organizations to conduct research
  related to development of treatment for liver
  fibrosis and other fatty liver disease is
  expected to spur growth of liver fibrosis
  treatment market. For instance, in August 2018
  professor from College of Science at Virginia
  Tech and Department of Pharmacology at the
  University of Virginia received US 400,000 grant
  from the Virginia Biosciences Health Research
  Corporation (VBHRC) with US 800,000 matching
  funds from Continuum Biosciences, Inc. This grant
  along with matching funds will help researchers
  to develop drugs to treat nonalcoholic
  steatohepatitis (NASH).

4

• Global Liver Fibrosis Treatment Market Value (US
  Mn), by Region, 2026

5

• Growing Research and Developments (RD)
  Activities and New Developments for Liver
  Fibrosis Treatment are expected to Augment Market
  Growth
• Liver fibrosis results from various chronic
  injuries and it often progresses to liver
  cirrhosis, liver failure, portal hypertension,
  and hepatocellular carcinoma. Moreover, liver
  transplantation is only treatment available for
  advanced stage liver fibrosis. Therefore, new
  treatment strategies are currently in clinical
  development stages to treat the liver fibrosis.
  These treatment option include inhibition of
  hepatic injury, inhibition of activation of
  Hematopoietic Stem Cells (HSCs), and inhibition
  of proliferation of HSCs, inhibition of
  deposition of type I collagen and proliferation
  of HSCs. Treatment options for liver fibrosis are
  usually depends on the underlying cause of the
  fibrosis. A healthcare professional can treat the
  underlying liver fibrosis illness conditions, to
  reduce the effects of liver disease.
• Furthermore, key players in the liver fibrosis
  treatment market are engaged in pre-clinical and
  clinical studies to develop novel treatment
  therapies in liver fibrosis regime. For instance,
  in March 2018, the U.S. FDA granted Orphan Drug
  Designation for PTG-300 a subcutaneous
  injectable developed by Protagonist Therapeutics,
  Inc. The PTG-300 is currently in clinical
  development stage for the potential treatment of
  beta-thalassemia, and can also be used in the
  liver fibrosis treatment.

6

• For instance, Gilead Sciences, Inc., in October
  2017, released the Phase II result studies for
  Selonsertib GS-0976 in Nonalcoholic
  Steatohepatitis (NASH) stage F3 liver fibrosis.
  These studies reported that, GS-0976 led to
  significant reductions in concentration of liver
  fat and fibrosis. Moreover, Gilead Sciences also
  contain 18 other pipeline molecules in the liver
  fibrosis treatment, which is further expected to
  boost companys revenue in near future.
• In April 2017, Tobira Therapeutics, Inc.
  initiated the clinical study to confirm the
  efficacy and safety of cenicriviroc (CVC) for the
  treatment of liver fibrosis in adult patients
  with NASH. The study is expected to complete in
  July 2019.
• In April 2017, Bristol-Myers Squibb Company
  presented the Phase II clinical trial study of
  BMS-986036 a human fibroblast growth factor. The
  study results reported that BMS-986036 shows
  consistent improvement in liver fat, liver
  injury, and liver fibrosis in patients with
  Nonalcoholic Steatohepatitis (NASH). Increasing
  number of clinical trials are currently in
  process for the treatment of liver fibrosis,
  which are expected to augment the market growth
  over the forecast period.

7
Global Liver Fibrosis Treatment Market Share (),
By Treatment Type 2018 2026

8

• North America market accounted for the largest
  market share, followed by Europe in 2018. This is
  owing to increasing burden of potential risk
  factors leading to liver fibrosis such as
  obesity, type 2 diabetic, metabolic fibrosis,
  alcoholic fibrosis, non-alcoholic steatohepatitis
  (NASH), non-alcoholic fatty liver disease
  (NAFLD), among others. For instance, according to
  the NASH Education Program, 2018 data findings,
  NAFLD is most common chronic liver condition in
  Western population of economies in the Europe and
  the U.S. region as compared to obesity and type 2
  diabetes epidemics. Furthermore, the prevalence
  of NASH is expected to increase by 63 between
  2015 and 2030, leading to NASH become a major
  cause of liver transplantation in the U.S. by
  2020.
• Furthermore, according to the World Health
  Organization (WHO), in 2016 more than 1.9
  billion adults, 18 years and older were
  overweight, among which around 650 million were
  obese. According to Organisation for Economic
  Co-operation and Development (OECD) Obesity
  Update 2017 report, obesity levels are expected
  to be particularly high in the U.S., Mexico and
  U.K., where 47, 39 and 35 of the population
  respectively are projected to be obese in 2030.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/liver-fibrosis-treatment-market-232
  0

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/